Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.73
-0.0900-0.22%
Post-market: 40.730.00000.00%19:30 EDT
Volume:53.73K
Turnover:2.19M
Market Cap:1.04B
PE:- -
High:40.88
Open:40.82
Low:40.53
Close:40.82
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:0.06
T/O Rate:0.21%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos® (Mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm) in Adults and Pediatric Patients*

THOMSON REUTERS
·
Oct 01

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01

Bristol-Myers Squibb's Camzyos to Treat Heart Condition Receives FDA Approval for Pediatric Patients

MT Newswires Live
·
Oct 01

FDA: Approved Camzyos (Mavacamten) Capsules as First Treatment for Children with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Website

THOMSON REUTERS
·
Oct 01

FDA Approves First Drug to Improve Functional Capacity and Symptoms in Children with Rare Inherited Heart Condition

THOMSON REUTERS
·
Oct 01

FDA: Camzyos Carries Boxed Warning for Heart Failure Risk, Restricted to Rems Program

THOMSON REUTERS
·
Oct 01

FDA approves Bristol Myers’ Camzyos capsules for children with oHCM

TIPRANKS
·
Oct 01

Dow Drops 150 Points on Losses for Shares of Sherwin-Williams Co., Merck

Dow Jones
·
Oct 01

Sector Update: Healthcare

MT Newswires Live
·
Oct 01

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

MT Newswires Live
·
Oct 01

BMY Expands Real-World Cancer Data With New AUGTYRO Study in Korea

TIPRANKS
·
Oct 01

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
Oct 01

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

TIPRANKS
·
Oct 01

AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline

TIPRANKS
·
Oct 01

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30